Bertis Joins the Ministry of Science and ICT’s‘Development of Technologies for Spatial Proteomics-BasedMulti-Omics Analysis’ Project- 6 institutions participate with a total research budget of approximately 9 billion KRW over 4 years and 6 months-Bertis participates in securing global-level spatial proteomics technologies with its expertise in proteomics-based biomarkersOn September 6, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced its participation as a research institution in the ‘Development of Materials and Component Technologies for Spatial Proteomics-Based Multi-Omics Analysis’ project (Project No. RS-2024-00454407), led by the Ministry of Science and ICT and the National Research Foundation of Korea.This project is part of the ‘2024 Nano and Materials Technology Development Project’ initiated by the Ministry of Science and ICT and the National Research Foundation of Korea. It aims to secure global-level technologies that will drive the creation of new industries and advance key sectors, while also expanding research infrastructure and promoting commercialization.Bertis will collaborate with the institution in charge of research, University of Ulsan College of Medicine, Meteor Biotech, Korea Animal Model Archive, Future Medicine Research Institute of CHA Bundang Medical Center of CHA University, and the Korea Basic Science Institute to form the 'Spatial Proteomics Technology Development Research Consortium.' The consortium will undertake the project to develop spatial proteomics technologies for multi-omics, with a total research budget of 9 billion KRW, until December 2028.Spatial proteomics technology is a field that studies the spatial distribution and interactions of proteins within tissues. No commercialized technologies for spatial proteomics analysis exist, and single-cell preprocessing methods are being used as alternatives. This project will develop novel materials and foundational technologies for protein digestion, which are currently unavailable in spatial proteomics processes. The goal is to establish the first global analysis platform, from tissue separation to diagnosis, build databases, develop AI software, and create biomarkers for various cancers.Bertis, recognized for its technological prowess in developing and utilizing proteomics-based biomarkers, will be responsible for establishing LC-MS analysis conditions using single-cells, developing spatial proteomics-specific preprocessing materials and POC (Proof of Concept), creating quality control software for fragmented tissue proteomics analysis platforms, and developing and training AI algorithms through pathology image analysis.Kyunggon Kim, a professor in the Department of Digital Medicine at the University of Ulsan College of Medicine, head of the institution in charge of research, stated, "Spatial multi-omics is increasingly recognized as a key platform for translational research and new drug development. However, spatial proteomics is a field that demands advanced technology and material development. We are excited to collaborate with outstanding government-funded research institutions, hospitals, and companies with core technologies, such as Bertis and Meteor Biotech to conduct challenging research.”Un-beom Kang, Head of Bertis Biomarker Research Institute and co-leader of the research, explained, “The field of proteomics has high technological utility and remarkable growth within the biotech industry, accompanied by intense global competition to secure technological superiority and foundational technologies for disease diagnosis and treatment. As a leader in the proteomics industry with expertise in commercializing technology and applying AI, Bertis is dedicated to achieving significant results in the development of spatial proteomics technologies through collaboration with leading domestic research institutions."Meanwhile, Bertis has established its proprietary analysis system for single-cell proteomics research and is accelerating the advancement of proteomics-based precision medicine technologies by utilizing AI. The company is enhancing the accuracy of early diagnostic solutions for breast cancer, pancreatic cancer, and ovarian cancer through machine learning-based algorithms. It is also developing the SAN (Spectrum is All you Need) model, which uses large language models (LLM) to analyze protein distribution data and extract health information related to the presence or absence of target diseases.

Bertis and Rokit Genomics Sign MoU for Collaboration on Proteomics and Genomics Analysis Services - Collaborating on single-cell proteomics and genomics analysis services to provide single-cell multi-omics analysis services and advance joint technology development <Photo: Bertis CEO Seung-man Han (left) and Rokit Genomics CEO Tae-woo Kwon commemorate the signing of the MoU.> On August 26th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it signed a Memorandum of Understanding (MoU) with Rokit Genomics, a single-cell analysis company (led by CEOs Tae-woo Kwon and Yoon-Ki Gil). Under this MoU, Bertis and Rokit Genomics plan to collaborate on the development and marketing of proteomics and genomics analysis services based on their expertise in single-cell analysis technology. They also will work together on future joint technology development. Single-cell analysis is a technique that distinguishes biological characteristics at the level of individual cells. It enables high-sensitivity and high-resolution analysis of rare cells or low-expressed genomics and proteomics. This method is utilized in various research fields including cancer, Alzheimer's, autoimmune diseases, and infectious diseases. The single-cell analysis market is expected to grow significantly, reaching approximately 19 trillion KRW globally by 2030. Single-cell proteomics analysis is a technology that qualitative and quantitative analysis of proteins at the single-cell level. This technique allows detailed analysis of disease-specific proteins, minimizing the loss of cellular diversity information that can occur in tissue or cultured cell analyses. This technology is expected to advance the application of precision medicine through cell-specific analysis. Bertis, which has secured the technology to analyze the proteome of trace samples through next-generation mass spectrometry technology, offers single-cell proteomics analysis of over 5,000 proteins and has launched Korea's first single-cell proteome profiling service based on this cutting-edge technology. Rokit Genomics provides customer-specific analysis services using single-cell genomics sequencing. Rokit Genomics focuses on cell heterogeneity, rare cells, cell lineage relationships, and biomarker discovery by analyzing genomic data collected from individual cells. Leveraging extensive experience with samples from human tissues to plants and animals, Rokit Genomics performs analyses across requests. Kwon Tae-woo, the CEO of Rokit Genomics, stated, “With the rise of genomics and proteomics technologies, there is an increasing demand for combined analytical methods in drug discovery and candidate development. Our collaboration with Bertis, which possesses expertise in proteomics analysis, will be a milestone in expanding Rokit Genomics' multi-omics analysis capabilities. We expect to lead the popularization of single-cell analysis through advanced customer-specific consulting.” Seung-man Han, the CEO of Bertis, emphasized, “As a leader in proteomics technology, we have equipped ourselves with the latest equipment and expertise to offer single-cell proteomics technology to domestic researchers. Through this service collaboration with Rokit Genomics, a pioneer in single-cell sequencing, we hope to raise awareness of single-cell proteomics analysis among bioindustry and academic researchers and to expand our collaborative technology development.” Furthermore, Bertis’ omics analysis solution, PASS (Pan-omics Analysis Service & Solution), provides customized proteomics analysis solutions for biomarker discovery, validation, drug research and development, and production based on client’s needs. The service caters to a range of clients, including biotech and CDMO enterprises developing new modality drugs, and has completed 103 projects for 54 clients as of July 2024, driven by satisfaction with data quality and customized consulting.

Bertis to Participate in Korea's Largest Proteomics Conference, KHUPO 2024 - Poster presentation on research outcomes in biomarker candidates for prostate cancer diagnosis, and an educational lecture on QC and interpretation of mass spectrometry-based proteomics data- Setup of a promotional booth from June 25 to 27 to introduce the mass spectrometry-based omics analysis solution PASS, and its customized peptide synthesis solution, PEPS PRO. On June 25th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in 'KHUPO 2024 YEOSU (KHUPO 2024)', the largest domestic proteomics conference hosted by The Korean Human Proteome Organization (KHUPO). <Image: Logos of KHUPO and Bertis> KHUPO 2024, to be held from June 25 to 27 at the Yeosu Expo Convention Center, is expected to be a platform for sharing new research achievements and innovative technologies in the field of proteomics under the theme "PROUD: PROteomics Unlimited Desire." As a leading domestic company in the proteomics field, Bertis will present research achievements, conduct educational sessions, and operate a promotional booth during KHUPO 2024.Dr. Jin-Young Cho from the Biomarker Research Team at Bertis R&D division will present a poster on "Novel Diagnostic Biomarkers for Prostate Cancer Discovered Using a Mass Spectrometry-Based Pipeline" on Wednesday, the 26th at 11:45 AM, and Thursday, the 27th at 11:30 AM. <Image: Discovery process of PCa biomarker candidates>Prostate Cancer(PCa) can often be detected by testing the levels of Prostate-Specific Antigen (PSA) in blood. However, the level of PSA is also rise in cases of benign prostatic hyperplasia and prostatitis, necessitating a more accurate diagnostic test specifically for PCa. In this study, the Bertis team used liquid chromatography data-independent acquisition tandem-mass spectrometry (LC-DIA-MS/MS) to analyze the human serum of 50 healthy controls (HCs), 42 individuals with benign conditions, and 90 patients with PCa. The aim was to discover potential biomarkers for PCa diagnosis. They identified 24 differentially expressed proteins (DEPs) in PCa patients compared to healthy controls and those with benign conditions. In addition, bioinformatic analysis on public data of prostate cancer-associated biomarkers and prognosis before and after treatment, a list of 50 proteins was created. Takes together, a total of 74 serum proteins were selected as potential prostate cancer biomarker candidates.In the education session, Dr. Sunghyun Huh, Head of the Bioinformatics Team at Bertis R&D division will deliver a lecture titled “Interpretation of Mass Spectrometry-Based Proteomics Data for Biological Research”. The session will introduce the analysis, processing, and interpretation of mass spectrometry-based proteomics data, covering relevant research examples. The lecture is scheduled for Wednesday, the 26th, at 9:00 AM in the 1st floor lecture hall, as the first session of ‘Education Session 3: Proteomics meets AI’During the event, Bertis will operate a promotional booth to showcase its mass spectrometry-based omics analysis solution, PASS (Pan-omics Analysis Service & Solution), alongside its customized peptide synthesis service, PEPS PRO. PEPS PRO provides synthesis services for customized peptides, PNAs, and various organic compounds utilizing the company’s GMP facilities and highly skilled professionals, ensuring high-quality products at competitive prices. The company plans to utilize the KHUPO 2024 platform to initiate a marketing campaign to promote PEPS PRO.Seung-man Han, CEO of Bertis, stated, "Bertis is advancing and commercializing proteomics technologies to contribute to the development of practical solutions in clinical settings for domestic biotech companies." He further emphasized, "We are dedicated to sharing innovative technologies and research outcomes to broaden the impact of proteomics in Korea and bolster technological competitiveness."

Bertis, Successful in Clinical Proteomics Technology Commercialization,Seeks International Business Partners at BIO USA 2024 - Participating in the world's largest bio conference, hosted by the Biotechnology Innovation Organization (BIO), from June 3-6 to explore business development opportunities with global bio and pharmaceutical companies. - Aiming to secure international business partners for proteomics-based early diagnostic tests through the 'Seoul Bio Forum' on June 3 and the 'Company Presentation' on June 5. On May 28th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in the world's largest bio conference, the 'BIO International Convention 2024' (BIO USA 2024), held at the San Diego Convention Center in the United States from June 3 to 6. At BIO USA 2024, where leading companies, research institutions, and investors from the global bio industry will gather, Bertis will conduct two company presentations. These presentations will highlight advancements in clinical proteomics technology and share the latest research developments and business achievements of Bertis, including their successfully commercialized proteomics-based early diagnostic test. Through these activities, Bertis aims to explore various business development opportunities with global bio and pharmaceutical companies. [Image] Bertis Bio USA 2024 Presentation Schedule The first company introduction presentation will take place on June 3rd, local time (PST), at 6:00 PM at the Aquillius Innovation Hub as part of the 'Seoul Bio Forum,' organized by Invest Seoul, Seoul BioHub, and others. The event is dedicated to fostering networking opportunities among Korean enterprises engaged in BIO USA 2024, venture capital firms seeking U.S. market entry and investment, and bio-tech and legal entities possessing the requisite expertise for U.S. expansion. Bertis will showcase its proteomics-based early diagnosis solution technology and outline its growth strategy. On the third day of the event, June 5th at 2:30 PM, Bertis will conduct a Company Presentation session at Hall A Company Presentation Theater4. During this session, Bertis will introduce its successfully commercialized proteomics-based early diagnostic blood test pipeline and its mass spectrometry-based omics analysis service PASS (Pan-omics Analysis Service & Solution) to global bio-pharmaceutical companies. The company aims to explore opportunities for overseas business partnerships and collaborations through this session. Seung-man Han, the CEO of Bertis, stated, "Proteomics will play a crucial role in addressing major challenges facing the medical and healthcare sectors worldwide, enabling precision medicine. Through this event, Bertis aims to share the excellence and commercial viability of our core technology. We also strive to secure business cooperation opportunities to accelerate the introduction of proteomics-based technologies and products into clinical practice." Furthermore, Bertis leads technological innovation in the field of clinical proteomics by leveraging ProteoID, its core technology framework spanning protein data analysis to product and service commercialization. In 2019, Bertis achieved the world's first commercialization of a proteomics-based early diagnostic blood test for breast cancer, MASTOCHECK®, in both domestic and Singaporean markets, conducting a cumulative total of 170,000 tests in South Korea. Currently, they are advancing the development of early diagnostic tests for pancreatic and ovarian cancers as part of their pipeline expansion.

Asia Proteomics Leader, Bertis, Participates in' Asia Summit on Global Health 2024' -Invited as the only Korean company to participate in the event hosted by the Hong Kong Special Administrative Region on May 16-17... Dr. Sangtae Kim, Chief Scientist of Informatics and AI, will attend as a speaker. -Sharing insights on proteomics technologies and applications that Asia should focus on, including early cancer detection blood tests, during the session on ‘Advancing Healthcare in Asia Through Innovation’ on May 17 [Image] Asia Summit on Global Health, Bertis Logo On May 16th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in the '4th Asia Summit on Global Health 2024 (ASGH 2024)', which will be held at the Hong Kong Convention and Exhibition Center (HKCEC) on May 16th and 17th.ASGH, jointly organized by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), aims to promote innovative medical technology development and support investment activation to seek a more sustainable future amid global issues such as aging population, novel infectious diseases, and climate-related health threats.At ASGH 2024, key officials from the governments of China and the Hong Kong Special Administrative Region, as well as executives from global leading pharmaceutical and biotech companies and research institutions, buyers, and investors active in the Asian region, will participate. Themed ‘Innovation, Inclusion, Impact’, ASGH 2024 will compromise a series of thematic sessions focusing on the latest trends in different medical sectors. Project pitching and deal-making meetings will also be organized to facilitate business discussions and investment partnerships. Bertis, as a leader in Asia's proteomics, is invited as the only Korean company to participate. Dr. Sangtae Kim, Chief Scientist of Informatics and AI at Bertis, will speak, introducing proteomics technologies that Asia's medical industry should focus on for development, and will share insights into their applications and importance.Dr. Kim will participate in the session titled 'Advancing Healthcare in Asia Through Innovation' on May 17th. He will highlight how proteomics technology is rapidly advancing and providing opportunities for precise disease diagnosis, personalized treatment tailored to individuals, and drug target discovery. Particularly, he will introduce proteomics-based early cancer detection blood tests as an innovative technology that will bring significant changes to the healthcare industry in Asia. He plans to emphasize the importance of investing in and leading the development of proteomics technology and industry in the Asian region.Dr. Kim stated, "I am honored to have the opportunity to discuss the future direction of Asian healthcare with global leaders in Hong Kong, the hub of Asia. Proteomics technology is essential for realizing precision medicine and plays a crucial role in addressing key challenges faced by the healthcare sector in Asia. I will do my utmost to promote regional collaboration and highlight the importance of this technology in overcoming these challenges."Bertis combines more than a decade of accumulated expertise in proteomics with bioinformatics to identify biomarkers for various major diseases, including cancer. These biomarkers are then utilized in the development of diagnostic and analytical solutions. In 2019, Bertis introduced MASTOCHECK®, the world's first proteomics-based early breast cancer detection blood test. The company is currently working on developing early detection blood tests for pancreatic cancer and ovarian cancer as part of its ongoing pipeline. Additionally, Bertis is engaged in the research and development of SAN (Spectrum is All you Need) model, aiming to create an innovative health information interpretation model that can extract health insights from proteomic biological data using AI technology.